SCHEMBL2190191

SCHEMBL2190191

CC(C)(C)OC(=O)C(N)c1cc(C(=O)O)no1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
HPGD P15428 2/20 0.36
MAPT P10636 1/20 0.36
RECQL P46063 1/20 0.36
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
SLC7A5 Q01650 1/20 0.35
PTPN1 P18031 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
LMNA P02545 1/20 0.33
KMT2A Q03164 1/20 0.33
SCD O00767 2/20 0.33
CDH1 P12830 1/20 0.31
CTNNB1 P35222 1/20 0.31
TCF7L2 Q9NQB0 1/20 0.31
EDNRA P25101 1/20 0.31
HCAR2 Q8TDS4 1/20 0.31
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27594090 0.79 MEN1 (0.46) ALDH1A1MAPTSMN1; SMN2KMT2ASCD
SCHEMBL3586133 0.74 C3AR1 (0.36) LMNAKMT2AEDNRA
SCHEMBL12590876 0.74 KMT2A (0.45) ALDH1A1HPGDMAPTSMN1; SMN2LMNA
SCHEMBL2058770 0.74 KMT2A (0.45) ALDH1A1HPGDMAPTSMN1; SMN2LMNA
SCHEMBL4203152 0.74 KMT2A (0.45) ALDH1A1HPGDMAPTSMN1; SMN2LMNA
SCHEMBL20780860 0.73 SMN1; SMN2 (0.44) ALDH1A1HPGDMAPTRECQLCYP2C19
SCHEMBL4443700 0.72 ALDH1A1 (0.41) ALDH1A1MAPTRECQLCYP2C9CYP2C19
SCHEMBL27612493 0.72 CYP1A2 (0.46) ALDH1A1HPGDMAPTRECQLCYP2C19
SCHEMBL27612483 0.72 TP53 (0.42) MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL28754854 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973061-B2 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2011-07-05 US disclosed
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2009-07-23 US disclosed
EP-1730128-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2006-12-13 EP disclosed
WO-2005097765-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE ALK, BCL3, MCL1 ALDH1A1 1466/4885HPGD 3481/4885MAPT 4524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.